— Latest update: May 2022 —
With an ever-increasing number of bio-ventures and the establishment of a new ecosystem in the Japanese biotech field, this sector offers many opportunities for European SME companies. Through industrial, academic, government and international collaboration, various programs are being promoted and implemented. Due to Japan’s population aging and the resulting health issues, the pharmaceutical sector remains an especially attractive market, as evidenced by the high number of deals between European investors and Japanese biopharma in 2021.
How is Japanese biotech R&D structured, who are the key stakeholders, and how can European SMEs profit and find Japanese partners? Japan spends consistently over 3% of its GDP on R&D, of which some 70
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
No less than 300 web pages with up-to-date information on Japan, more than 170 reports available as well as a lot of detailed information on the Japanese business culture.